CAS No.
[1231929-97-7 (Unlabeled)]
Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Refer MSDS for complete information
Synonyms
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine-d5; N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine-d5
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Abemaciclib-d5 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Abemaciclib-d5 usage and description
Abemaciclib D5 is a chemical compound that is used in the treatment of breast cancer. It is a potent and selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), which are enzymes involved in cell division. By inhibiting these enzymes, Abemaciclib D5 slows down the growth of cancer cells and prevents them from dividing and multiplying.
The usage of Abemaciclib D5 is primarily for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is generally administered orally, with the recommended dose being 150 mg twice daily. The dosage may vary depending on the patient's condition and response to treatment.
Chemically, Abemaciclib D5 is a deuterated version of Abemaciclib, which means that it contains five atoms of deuterium. Deuterium is a stable isotope of hydrogen that has been used in the development of drugs to improve their pharmacokinetic properties, such as bioavailability, half-life, and metabolic stability.
Abemaciclib D5 has been extensively studied in preclinical and clinical trials, and it has been shown to have a favorable safety profile. However, like any other drug, it may cause side effects, such as diarrhea, nausea, fatigue, and decreased appetite. Patients taking Abemaciclib D5 should be closely monitored by healthcare professionals to manage any adverse reactions.
